Mogrify® is a proprietary direct cellular conversion technology, which addresses the speed and efficiency of cell conversions through the identification of key regulatory switches, such as transcription factors, for the development of scalable cell therapies.
With the capacity to convert any human cell type into any other, Mogrify represents a unique opportunity to transform the development of ex vivo cell therapies or in vivo reprogramming therapies for diseases with a high unmet clinical need.
As an example, fibroblasts can be acquired from a patient by skin biopsy, and T-cells from the blood. The RNA of these cells is then sequenced in order to compare the gene expression levels in the context of all other possible cell types.
Simultaneously, local transcriptomic regulatory networks are built around each regulatory gene (e.g. transcription factors) in the human genome to calculate and rank the effect of the genes on the desired cell conversion by querying large-scale regulatory networks. The optimal combination of key regulators is predicted to maximize network coverage while avoiding redundancies.
Once this optimal combination has been identified, the DNA sequence of each regulatory gene is encoded into delivery vectors (such as viral vectors), which are transduced into the fibroblast causing changes in DNA expression profile and therefore switching the genetic programs of the cell which induces the conversion of the fibroblasts into mature T-cells with cytotoxic capabilities.
This process can quickly and systemically be reproduced to enhance existing stem-cell forward reprogramming methods or to bypass development pathways altogether affecting a direct transdifferentiation between any starting cell type and any other clinically valuable cell type.
Bypasses development pathways altogether effecting direct transdifferentiation between a mature cell type to another.
Produces mature cells to avoid the tumorigenicity- and immunogenicity-associated characteristics of pluripotent stem cells.
Queries FANTOM5 and other proprietary data sources to improve prediction quality, prediction accuracy and cell conversion efficacy.
Produces any target cell type from any source cell type.
Capacity to identify small molecules known to affect the expression of the key Mogrify predicted transcription factors, avoiding the need for their transduction, and offering greater potential as an in vivo reprogramming therapy.
10 Considerations for Enhancing Your iPSC Processing Pipeline
How can you enhance your induced pluripotent stem cell (iPSC) processing pipeline? In this infographic, discover 10 questions you should answer to optimize your iPSC processing pipeline, enhance your protocols and ensure you have achieved your desired cell type.
Webinar: A Systematic Approach for Driving Cell Identity and Accelerating Regenerative Medicine
Discover high-resolution data, computational power, and novel algorithms as a means of exploring transcriptomic networks, systematically discovering the key regulatory switches driving cell identity and accelerating regenerative medicine.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.